Emphysema

5
Pipeline Programs
7
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

CSL Behring
CSL BehringIL - Bradley
1 program
1
Alpha1- proteinase inhibitor [human]Phase 41 trial
Active Trials
NCT00670007Completed140Est. Sep 2014
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
Zephyr endobronchial valvePhase 31 trial
Implementation of 9 mm intrabronchial valvesN/A1 trial
Active Trials
NCT03008226Unknown120Est. Aug 2017
NCT00613860Withdrawn0Est. Apr 2012
Olympus
OlympusPA - Center Valley
6 programs
1
Intra Bronchial ValvePhase 21 trial
IBV® Valve SystemN/A1 trial
OL-BF-001N/A1 trial
Spiration Valve SystemN/A1 trial
Spiration Valve SystemN/A1 trial
+1 more programs
Active Trials
NCT00475007Completed277Est. Aug 2017
NCT02470052Terminated38Est. Aug 2018
NCT04302272Recruiting150Est. Apr 2028
+3 more trials
Grifols
GrifolsNEW YORK, NY
1 program
1
Prolastin-C, 60 mg/kgPhase 21 trial
Active Trials
NCT01213043Completed30Est. Jan 2012
Arda Therapeutics
Arda TherapeuticsCA - San Carlos
1 program
1
Autologous MSCs transplantationPhase 11 trial
Active Trials
NCT01758055UnknownEst. Jan 2014
XVIVO
XVIVOSweden - Mölndal
2 programs
Steen Solution™N/A1 trial
Transplantation of lungs obtained from Non-Heart-Beating DonorsN/A1 trial
Active Trials
NCT01241942TerminatedEst. Mar 2013
NCT01615484CompletedEst. Jan 2017
Siemens Healthineers
Siemens HealthineersGermany - Forchheim
1 program
Stereotactic Ablative RadiotherapyN/A1 trial
Active Trials
NCT03673176CompletedEst. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
CSL BehringAlpha1- proteinase inhibitor [human]
Heidelberg PharmaZephyr endobronchial valve
GrifolsProlastin-C, 60 mg/kg
OlympusIntra Bronchial Valve
Arda TherapeuticsAutologous MSCs transplantation
OlympusSpiration Valve System
OlympusSpiration Valve System
OlympusOL-BF-001
Heidelberg PharmaImplementation of 9 mm intrabronchial valves
XVIVOTransplantation of lungs obtained from Non-Heart-Beating Donors
OlympusSpiration Valve System
Siemens HealthineersStereotactic Ablative Radiotherapy
XVIVOSteen Solution™
OlympusIBV® Valve System

Clinical Trials (14)

Total enrollment: 1,027 patients across 14 trials

NCT00670007CSL BehringAlpha1- proteinase inhibitor [human]

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Start: Apr 2008Est. completion: Sep 2014140 patients
Phase 4Completed
NCT00613860Heidelberg PharmaZephyr endobronchial valve

Sequential Endoscopic Lung Volume Reduction

Start: Jan 2008Est. completion: Apr 20120
Phase 3Withdrawn
NCT01213043GrifolsProlastin-C, 60 mg/kg

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Start: Nov 2010Est. completion: Jan 201230 patients
Phase 2Completed
NCT00145548OlympusIntra Bronchial Valve

Pilot Study of the Spiration IBV™ System

Start: Dec 2003Est. completion: Aug 200791 patients
Phase 2Completed
NCT01758055Arda TherapeuticsAutologous MSCs transplantation

Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients

Start: Dec 2012Est. completion: Jan 2014
Phase 1Unknown
NCT04302272OlympusSpiration Valve System

STRIVE Post-Market Registry Study

Start: Oct 2021Est. completion: Apr 2028150 patients
N/ARecruiting
NCT02914340OlympusSpiration Valve System

REACH SVS Control Patient Cross-Over Study

Start: Sep 2016Est. completion: Sep 20189 patients
N/ACompleted
NCT02470052OlympusOL-BF-001

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Start: Aug 2015Est. completion: Aug 201838 patients
N/ATerminated
NCT03008226Heidelberg PharmaImplementation of 9 mm intrabronchial valves

Spiration Valve System 9 mm European Post Market Evaluation Study

Start: Jun 2015Est. completion: Aug 2017120 patients
N/AUnknown
NCT01615484XVIVOTransplantation of lungs obtained from Non-Heart-Beating Donors

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Start: Sep 2013Est. completion: Jan 2017
N/ACompleted
NCT01812447OlympusSpiration Valve System

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

Start: Jun 2013Est. completion: Aug 2022172 patients
N/ACompleted
NCT03673176Siemens HealthineersStereotactic Ablative Radiotherapy

Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy

Start: Feb 2013Est. completion: Aug 2021
N/ACompleted
NCT01241942XVIVOSteen Solution™

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Start: Dec 2010Est. completion: Mar 2013
N/ATerminated
NCT00475007OlympusIBV® Valve System

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

Start: Sep 2007Est. completion: Aug 2017277 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,027 patients
7 companies competing in this space